Trials / Conditions / Anti-Infective Agents

Anti-Infective Agents

18 registered clinical trials studyying Anti-Infective Agents.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections - Canada NCT07189858	Ondine Biomedical Inc.	N/A
Active Not Recruiting	Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections NCT06702878	Ondine Biomedical Inc.	Phase 3
Completed	Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falci NCT05979207	Medicines for Malaria Venture	Phase 1
Completed	Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products NCT02242968	National Institute of Allergy and Infectious Diseases (NIAID)	—
Terminated	Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM NCT04489420	Celularity Incorporated	Phase 1
Unknown	A Digital Antimicrobial Stewardship Smartphone Application to Combat AMR: the AB-assistant NCT03793946	Annelies Verbon	N/A
Unknown	Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 NCT04365101	Celularity Incorporated	Phase 1 / Phase 2
Terminated	Natural Killer Cell (CYNK-001) Infusions in Adults with AML NCT04310592	Celularity Incorporated	Phase 1
Completed	Neuroimmune Dysfunction in Alcohol Use Disorder NCT04210713	University of Maryland, Baltimore	Phase 1
Completed	Compliance of Initial Empiric Antimicrobial Therapy NCT04448665	Military Institute od Medicine National Research Institute	—
Completed	Safety, PK, and PD Study of IVRs Releasing TFV and LNG NCT03279120	CONRAD	Phase 1
Completed	Probiotics to Promote Intestinal Health NCT02046512	Washington University School of Medicine	Phase 4
Completed	Acceptability Study of Vaginal Films for HIV Prevention NCT01231763	University of Pittsburgh	—
Completed	Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction NCT01244698	Stony Brook University	Phase 4
Completed	Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension NCT01105208	Bayer	Phase 1
Completed	Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules NCT01073553	Bayer	Phase 1
Completed	Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension NCT01073540	Bayer	Phase 1
Completed	Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic NCT01690533	Bayer	—